Please sign in to follow a disease.
Hepatitis D virus infection
MONDO:0005789Inflammation of the liver in humans caused by hepatitis delta virus, a defective RNA virus that can only infect hepatitis B patients. For its viral coating, hepatitis delta virus requires the hepatitis B surface antigens produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Also known as: HDV, Hepatitis D, Hepatitis D virus, Hepatitis delta virus caused hepatitis, Hepatitis delta virus hepatitis, hepatitis delta, hepatitis type D
214 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New hope for hepatitis delta: phase 3 trial of brelovitug launches
Disease control OngoingThis Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is re…
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tame rare liver virus
Disease control OngoingThis phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus le…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for hepatitis delta: expanded access to bulevirtide
Disease control APPROVED_FOR_MARKETINGThis study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is …
Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug duo aims to control hard-to-treat hepatitis delta
Disease control OngoingThis phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise against rare liver virus
Disease control OngoingThis study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting. The goal is to see if the drug can lower the virus level and improve liver h…
Phase: PHASE2, PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare liver infection: RBD1016 trial underway
Disease control OngoingThis study tests an experimental drug called RBD1016 in 14 adults with chronic hepatitis D, a serious liver infection. The main goal is to see if the drug can lower the amount of virus in the blood over 60 weeks. Participants receive either RBD1016 or a placebo and visit the clin…
Phase: PHASE2 • Sponsor: Ribocure Pharmaceuticals AB • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug duo takes on rare liver virus in head-to-head trial
Disease control OngoingThis study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Pharmacists take on heart disease: new study tests community-based risk reduction
Disease control OngoingThis study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug shows promise against rare liver infection
Disease control OngoingThis Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the v…
Phase: PHASE2 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug bulevirtide tracked in real-world hepatitis d patients
Disease control OngoingThis study follows 170 people with chronic hepatitis D who are taking bulevirtide to see how well it works over time and what side effects may occur. Researchers will track serious liver problems like liver failure, cancer, or need for transplant. The goal is to understand the dr…
Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can video chats curb drinking in liver patients? new trial aims to find out
Disease control OngoingThis study tests whether a stepped alcohol treatment delivered via video or phone calls can help people with advanced liver disease cut back on unhealthy drinking. About 180 participants will be randomly assigned to either the treatment program or usual care. The goal is to see i…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 26, 2026 18:07 UTC
-
New MRI dye could sharpen liver lesion detection
Diagnosis ENROLLING_BY_INVITATIONThis study compares a new MRI contrast agent, gadopiclenol, to the standard agent, gadoxetate, for imaging liver lesions. Researchers will enroll 23 adults with chronic liver disease or known liver lesions to see if gadopiclenol provides equal or better image quality and lesion v…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New blood test could spot liver cancer sooner
Diagnosis ENROLLING_BY_INVITATIONThis study is testing whether a new blood test score, called GAAD, can detect liver cancer earlier in people with chronic liver disease. The GAAD score combines a person's gender, age, and two blood markers (AFP and PIVKA-II). Researchers will compare the GAAD score to standard u…
Phase: NA • Sponsor: Mahidol University • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC
-
NIH launches Long-Term observation of inflammatory diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Liver health may change how this drug works
Knowledge-focused OngoingThis study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Pandemic's hidden toll: frailty rises in liver transplant hopefuls
Knowledge-focused OngoingThis study examines whether the COVID-19 pandemic increased frailty and muscle loss (sarcopenia) in people waiting for a liver transplant. Researchers will compare data from 208 patients assessed before and during the pandemic. The goal is to understand how the pandemic affected …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can an iPad test spot brain fog before liver surgery?
Knowledge-focused OngoingThis study looks at whether an electronic cognitive test called BrainCheck can effectively screen mental function in 100 patients scheduled for liver surgery. Researchers will compare how well patients complete the digital test versus a traditional pen-and-paper assessment. The g…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive data dive aims to improve GI care
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a registry that will review medical records of 1,000 patients treated for benign or malignant gastrointestinal diseases between 2005 and 2030. Researchers will look at survival, symptoms like heartburn and swallowing trouble, and quality of life. The goal is to lear…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver disease growth study cancelled before it began
Knowledge-focused TerminatedThis study planned to test a growth factor medicine (Increlex) in children aged 4-18 with chronic liver disease and short stature. The goal was to see if it could improve growth and quality of life. However, the study was withdrawn before any participants were enrolled, so no res…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
AI predicts hospital stays, but study never started
Knowledge-focused TerminatedThis study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Stomach ultrasound could spot liver trouble early
Knowledge-focused OngoingThis study looks at whether a new ultrasound technique done through the stomach (endoscopic ultrasound elastography) can better predict serious liver problems in people with chronic liver disease. Researchers will measure liver and spleen stiffness in 50 patients and compare resu…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
500,000-Patient study aims to unlock secrets of chronic liver disease
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will follow up to 500,000 adults with chronic liver disease or cirrhosis to understand how the disease progresses and how treatments are used in everyday practice. Researchers will collect data from medical records and patient reports to improve care and …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Hope for hepatitis delta patients: study seeks to end lifelong treatment
Knowledge-focused OngoingThis study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…
Phase: NA • Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Study probes how poverty and support shape child transplant success
Knowledge-focused OngoingThis study looks at how social factors like income, education, and community support impact recovery in 500 children after liver transplant. Researchers will survey caregivers and interview families to understand barriers to good outcomes. The goal is to find ways to better integ…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
New diabetes drug tested in patients with liver problems
Knowledge-focused OngoingThis study looks at how a single dose of the experimental drug GZR4 injection behaves in people with mild, moderate, or severe liver impairment compared to those with normal liver function. The goal is to understand the drug's safety and how the body processes it. 36 adults with …
Phase: PHASE1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Withdrawn study sought safer biopsies for Bleeding-Prone patients
Knowledge-focused TerminatedThis study planned to test a technique called radiofrequency track cautery during liver, kidney, or spleen biopsies in patients at high risk for bleeding. The idea was to use a small heated probe to seal the biopsy track and reduce bleeding. However, the study was withdrawn befor…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Brain scans reveal hidden links between body diseases and metabolism
Knowledge-focused OngoingThis study watches 200 people with lung, gut, or hormone diseases over time using special brain scans (PET). It aims to see how these diseases change brain activity and whether those changes can predict tumor return, spread, or survival. No new treatment is tested—just observatio…
Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Tiny study hopes antiviral drug eases dangerous liver pressure
Knowledge-focused OngoingThis observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:20 UTC